446 related articles for article (PubMed ID: 3058398)
1. Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent.
Medansky RS; Bressinck R; Cole GW; Deeken JH; Ellis CN; Guin JD; Herndon JH; Lasser AE; Leibsohn E; Menter MA
Cutis; 1988 Nov; 42(5):480-5. PubMed ID: 3058398
[TBL] [Abstract][Full Text] [Related]
2. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.
Guenther LC; Poulin YP; Pariser DM
Clin Ther; 2000 Oct; 22(10):1225-38. PubMed ID: 11110233
[TBL] [Abstract][Full Text] [Related]
3. Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders.
Prakash A; Benfield P
Drugs; 1998 Jan; 55(1):145-63. PubMed ID: 9463794
[TBL] [Abstract][Full Text] [Related]
4. Mometasone furoate lotion once daily versus triamcinolone acetonide lotion twice daily in psoriasis.
Swinehart JM; Barkoff JR; Dvorkin D; Fisher G; Peets E
Int J Dermatol; 1989 Dec; 28(10):680-1. PubMed ID: 2687182
[No Abstract] [Full Text] [Related]
5. Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study.
Koo J; Cuffie CA; Tanner DJ; Bressinck R; Cornell RC; DeVillez RL; Edwards L; Breneman DL; Piacquadio DJ; Guzzo CA; Monroe EW
Clin Ther; 1998; 20(2):283-91. PubMed ID: 9589819
[TBL] [Abstract][Full Text] [Related]
6. Comparison of amcinonide ointment 0.1 percent twice daily and fluocinonide ointment 0.05 percent three times daily in the treatment of psoriasis.
Cornell RC
Cutis; 1983 May; 31(5):566-9. PubMed ID: 6851655
[TBL] [Abstract][Full Text] [Related]
7. Mometasone furoate 0.1%-salicylic acid 5% ointment twice daily versus fluocinonide 0.05% ointment twice daily in the management of patients with psoriasis.
Medansky RS; Cuffie CA; Tanner DJ
Clin Ther; 1997; 19(4):701-9. PubMed ID: 9377614
[TBL] [Abstract][Full Text] [Related]
8. [Topical treatment of dermatoses with difluocortolone valerate fatty ointment].
Carvajal Rosado VM
Z Hautkr; 1976; 51 Suppl 1():27-9. PubMed ID: 795183
[TBL] [Abstract][Full Text] [Related]
9. Treatment of psoriasis with amcinonide 0.1 percent and fluocinonide 0.05 percent ointments. A comparative double-blind study.
Engel MF
Cutis; 1982 Jun; 29(6):646-50. PubMed ID: 7049592
[TBL] [Abstract][Full Text] [Related]
10. Proactive maintenance therapy with a topical corticosteroid for vulvar lichen sclerosus: preliminary results of a randomized study.
Virgili A; Minghetti S; Borghi A; Corazza M
Br J Dermatol; 2013 Jun; 168(6):1316-24. PubMed ID: 23398459
[TBL] [Abstract][Full Text] [Related]
11. [Multicentre-clinical trial of the novel corticosteroid diflucortolone valerate in the forms of cream, ointment and fatty ointment. Part II: Comparative study with several commercial preparations (author's transl)].
Reckers VR; Wendt H
Arzneimittelforschung; 1976; 26(7b):1504-9. PubMed ID: 795434
[TBL] [Abstract][Full Text] [Related]
12. Are generic formulations equivalent to trade name topical glucocorticoids?
Stoughton RB
Arch Dermatol; 1987 Oct; 123(10):1312-4. PubMed ID: 3662563
[TBL] [Abstract][Full Text] [Related]
13. A novel formulation of mometasone furoate in psoriasis patients: a multicenter, randomized, double-blind clinical study.
Berg M; Svensson A; Faergemann J
Adv Ther; 2013 May; 30(5):503-16. PubMed ID: 23709257
[TBL] [Abstract][Full Text] [Related]
14. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting.
van de Kerkhof PC; van der Valk PG; Swinkels OQ; Kucharekova M; de Rie MA; de Vries HJ; Damstra R; Oranje AP; de Waard-van der Spek FB; van Neer P; Lijnen RL; Kunkeler AC; van Hees C; Haertlein NG; Hol CW
Br J Dermatol; 2006 Oct; 155(4):800-7. PubMed ID: 16965431
[TBL] [Abstract][Full Text] [Related]
15. A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis.
Green L; Sadoff W
J Cutan Med Surg; 2002; 6(2):95-102. PubMed ID: 11992180
[TBL] [Abstract][Full Text] [Related]
16. Bioavailability, antipsoriatic efficacy and tolerability of a new light cream with mometasone furoate 0.1%.
Korting HC; Schöllmann C; Willers C; Wigger-Alberti W
Skin Pharmacol Physiol; 2012; 25(3):133-41. PubMed ID: 22353786
[TBL] [Abstract][Full Text] [Related]
17. Once-daily 0.1% mometasone furoate cream versus twice-daily 0.1% betamethasone valerate cream in the treatment of a variety of dermatoses.
Viglioglia P; Jones ML; Peets EA
J Int Med Res; 1990; 18(6):460-7. PubMed ID: 2292327
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of hydrocortisone valerate 0.2 percent ointment in the treatment of atopic dermatitis.
Sefton J; Kyriakopoulos AA
Cutis; 1983 Jul; 32(1):89-91, 94. PubMed ID: 6349943
[TBL] [Abstract][Full Text] [Related]
19. A comparison of clobetasol propionate 0.05 percent ointment and an optimized betamethasone dipropionate 0.05 percent ointment in the treatment of psoriasis.
Jacobson C; Cornell RC; Savin RC
Cutis; 1986 Mar; 37(3):213-4, 216, 218-20. PubMed ID: 3514155
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of effectiveness and safety and quantitative evaluation of the use of fluocinolone acetonide in cream (0.025%) and medicated tape (8 micrograms/cm2) in the treatment of psoriasis].
Bedello P; De Paoli M
G Ital Dermatol Venereol; 1990 Jun; 125(6):XIX-XXI. PubMed ID: 2279744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
